Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 180Lymphoma 134Sarcoma 80Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Hodgkin Disease 50Lymphoma, Non-Hodgkin 49Leukemia 41Burkitt Lymphoma 40Lymphoma, Mantle-Cell 37Lymphoma, Follicular 34Neuroblastoma 30Ovarian Neoplasms 26Multiple Myeloma 26Neoplasms 24Lymphoma, Large-Cell, Anaplastic 23Carcinoma, Hepatocellular 23Neoplasm Metastasis 20Lymphoma, Large-Cell, Immunoblastic 19Triple Negative Breast Neoplasms 18HIV Infections 18Urinary Bladder Neoplasms 15Acquired Immunodeficiency Syndrome 15Osteosarcoma 14Liposarcoma 14Leiomyosarcoma 13Histiocytoma, Malignant Fibrous 13Breast Neoplasms, Male 13Lymphoma, B-Cell, Marginal Zone 12Inflammatory Breast Neoplasms 12

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Tamoxifen 1Paclitaxel 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Primary Breast Cancer × Doxorubicin × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡